Vyjuvek receives orphan drug designation in Japan for epidermolysis bullosa

The Japanese Ministry of Health, Labour and Welfare has granted Vyjuvek an orphan drug designation for the treatment of dystrophic epidermolysis bullosa, Krystal Biotech announced in a press release.
A noninvasive, topical, redosable gene therapy, Vyjuvek (beremagene geperpavec-svdt) delivers two copies of the COL7A1 gene to dystrophic epidermolysis bullosa (DEB) wounds.
In Japan, the orphan drug designation is meant to allow the company to prioritize consultation regarding development, reduce consultation fees, and receive tax incentives and subsidies for research into promising treatments for

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.